Exceptional response to neoadjuvant capecitabine and temozolomide in TSC2-mutant pancreatic neuroendocrine tumor
Tuberous Sclerosis 1/2 (TSC1/2) functions as a negative regulator of the mammalian target of rapamycin (mTOR) pathway, one of the key oncogenic pathways described in neuroendocrine neoplasm (NEN) carcinogenesis. While loss-of-function mutations in TSC1/2 lead to disinhibition of mTOR and uncontrolle...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-12-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621920300375 |